Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Intrathecal Baclofen in Spinal Spasticity: Frequency and Severity of Withdrawal Syndrome

I. Stetkarova, K. Brabec, P. Vasko, L. Mencl,

. 2015 ; 18 (4) : E633-E641.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc16010023

Grantová podpora
NT12282 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Intrathecal baclofen (ITB) delivered by programmable pump devices represents an important modality for long-term treatment of severe spinal spasticity. OBJECTIVE: One of the serious adverse events is a withdrawal syndrome after sudden interruption of ITB delivery. In this study, we analyzed the frequency and severity of this complication. Treatment recommendations follow. STUDY DESIGN: Case study. SETTING: Academic medical center. METHODS: A total of 54 ITB pumps were successfully implanted in 39 patients with severe intractable spasticity (24 with spinal cord injury, 15 with multiple sclerosis, 24 men, age range 21-59 years). RESULTS: Eight patients developed a withdrawal syndrome on total a daily dose of ITB between 90-420 μg/day. Seven patients had catheter-related complications. In one patient, pump failure was observed due to its corrosion. Within the group, baclofen withdrawal syndrome occurred once in 20.1 pump-years counted out of 160.4 pump-years of ITB treatment. LIMITATIONS: Small sample size. CONCLUSIONS: ITB withdrawal syndrome is a rare but life-threatening event and prompt diagnosis before treatment initiation is critical. The reported events were mostly mild due to the acute treatment regime and probably due to a lower dose of ITB. A prerequisite for successful ITB treatment is a deep knowledge of complications and their prompt management in the hands of a multidisciplinary team in specialized centers.

000      
00000naa a2200000 a 4500
001      
bmc16010023
003      
CZ-PrNML
005      
20240911165333.0
007      
ta
008      
160408s2015 xxu f 000 0|eng||
009      
AR
035    __
$a (PubMed)26218954
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Štětkářová, Ivana, $u Department of Neurology, Third School of Medicine, Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic; Department of Neurosurgery, Third School of Medicine, Hospital Kralovske Vinohrady, Charles University, Prague, Czech Republic. $d 1963- $7 xx0030376
245    10
$a Intrathecal Baclofen in Spinal Spasticity: Frequency and Severity of Withdrawal Syndrome / $c I. Stetkarova, K. Brabec, P. Vasko, L. Mencl,
520    9_
$a BACKGROUND: Intrathecal baclofen (ITB) delivered by programmable pump devices represents an important modality for long-term treatment of severe spinal spasticity. OBJECTIVE: One of the serious adverse events is a withdrawal syndrome after sudden interruption of ITB delivery. In this study, we analyzed the frequency and severity of this complication. Treatment recommendations follow. STUDY DESIGN: Case study. SETTING: Academic medical center. METHODS: A total of 54 ITB pumps were successfully implanted in 39 patients with severe intractable spasticity (24 with spinal cord injury, 15 with multiple sclerosis, 24 men, age range 21-59 years). RESULTS: Eight patients developed a withdrawal syndrome on total a daily dose of ITB between 90-420 μg/day. Seven patients had catheter-related complications. In one patient, pump failure was observed due to its corrosion. Within the group, baclofen withdrawal syndrome occurred once in 20.1 pump-years counted out of 160.4 pump-years of ITB treatment. LIMITATIONS: Small sample size. CONCLUSIONS: ITB withdrawal syndrome is a rare but life-threatening event and prompt diagnosis before treatment initiation is critical. The reported events were mostly mild due to the acute treatment regime and probably due to a lower dose of ITB. A prerequisite for successful ITB treatment is a deep knowledge of complications and their prompt management in the hands of a multidisciplinary team in specialized centers.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a baklofen $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D001418
650    _2
$a katétry $7 D057785
650    _2
$a selhání zařízení $7 D004868
650    _2
$a lidé $7 D006801
650    _2
$a implantabilní infuzní pumpy $7 D015918
650    _2
$a spinální injekce $7 D007278
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a roztroušená skleróza $x komplikace $7 D009103
650    _2
$a centrálně působící myorelaxancia $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D009125
650    _2
$a svalová spasticita $x komplikace $x farmakoterapie $7 D009128
650    _2
$a poranění míchy $x komplikace $7 D013119
650    _2
$a nemoci páteře $x komplikace $x farmakoterapie $7 D013122
650    _2
$a abstinenční syndrom $x diagnóza $x farmakoterapie $x etiologie $7 D013375
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Brabec, Karel $7 xx0322440
700    1_
$a Vaško, Peter $7 xx0087307
700    1_
$a Mencl, Libor $7 xx0210910
773    0_
$w MED00165489 $t Pain physician $x 2150-1149 $g Roč. 18, č. 4 (2015), s. E633-E641
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26218954 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160408 $b ABA008
991    __
$a 20240911165329 $b ABA008
999    __
$a ok $b bmc $g 1113452 $s 934391
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 18 $c 4 $d E633-E641 $i 2150-1149 $m Pain physician $n Pain Physician $x MED00165489
GRA    __
$a NT12282 $p MZ0
LZP    __
$a Pubmed-20160408

Najít záznam

Citační ukazatele

Možnosti archivace